116355-18-1

Usage

Uses

Used in Food Industry:
6-Bromo-7-methylimidazo[1,2-a]pyridine is used as a research subject to understand its presence in cooked meats and its potential health effects. The focus is on developing strategies to mitigate its presence in food products to ensure consumer safety.
Used in Research and Development:
6-Bromo-7-methylimidazo[1,2-a]pyridine is used as a subject of study in research to investigate its carcinogenic properties and potential health impacts on humans. This research aims to provide insights into the mechanisms of its formation in cooked foods and explore ways to reduce its formation and exposure to consumers.

InChI:InChI=1/C8H7BrN2/c1-6-4-8-10-2-3-11(8)5-7(6)9/h2-5H,1H3

Upstream product

• 107-20-0 2-chloroethanal 
• 98198-48-2 2-amino-5-bromo-4-methylpyridine 

Downstream Products

• 1464156-15-7 4-(6-bromo-7-methylimidazo[1,2-a]pyridin-3-yl)benzonitrile 
• 1464156-18-0 ethyl 4-(3-(4-cyanophenyl)-7-methylimidazo[1,2-a]pyridin-6-yl)benzoate 
• 1464156-21-5 4-(3-(4-cyanophenyl)-7-methylimidazo[1,2-a]pyridin-6-yl)benzoic acid 
• 1464156-26-0 tert-butyl 1-(4-(3-(4-cyanophenyl)-7-methylimidazo[1,2-a]pyridin-6-yl)benzoyl)-4-methylpiperidin-4-ylcarbamate 
• 1464151-74-3 4-(6-(4-(4-amino-4-methylpiperidine-1-carbonyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)benzonitrile 
• 1464151-75-4 4-(7-methyl-6-(4-(4-methylpiperazine-1-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)benzonitrile 

Relevant academic research and scientific papers

5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS

The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.

IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF

The invention provides compounds of formula (1), stereoisomers and tautomers thereof, or pharmaceutically acceptable salts, solvates and polymorphs thereof, and processes for their preparation. The invention further relates to pharmaceutical compositions containing said compounds and their use in the treatment of diseases or disorders mediated by one or more proinflammatory cytokines selected from TNF-a, IL-Ιβ, IL-6, IL-8, IL-12, IL-17 or IL-23.

BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF

The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.

BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF

The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases

INHIBITORS OF PI3 KINASE

The present invention relates to compounds of Formula I, II or III or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein